Added to YB: 2026-06-15
Pitch date: 2026-03-31
DNTH [neutral]
Dianthus Therapeutics, Inc.
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases.
Market Cap
$4.5B
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
-17.10
P/E
-19.70
EV/Sales
2.4K
Sector
Biotechnology
Category
growth
Show full summary:
Artisan Non-U.S. Small-Mid Growth Strategy Portfolio Holding: Dianthus Therapeutics, Inc.
DNTH (holding update): Clinical-stage biotech in complement antibodies for autoimmune diseases. +80% on Phase 3 CAPTIVATE CIDP interim results; lead asset claseprubart showed rapid efficacy ahead of timeline. Pipeline-in-a-product optionality (gMG, MMN). Thesis: multibillion potential like Argenx (bought ~$2B, exited ~$17B).
Read full article (1 min)